Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Trevena Inc (TRVN)

Trevena Inc (TRVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Trevena: Q1 Earnings Snapshot

Trevena: Q1 Earnings Snapshot

TRVN : 0.4000 (-4.08%)
Trevena: Q4 Earnings Snapshot

Trevena: Q4 Earnings Snapshot

TRVN : 0.4000 (-4.08%)
Trevena: Q3 Earnings Snapshot

Trevena: Q3 Earnings Snapshot

TRVN : 0.4000 (-4.08%)
Trevena: Q2 Earnings Snapshot

Trevena: Q2 Earnings Snapshot

TRVN : 0.4000 (-4.08%)
Trevena: Q1 Earnings Snapshot

Trevena: Q1 Earnings Snapshot

TRVN : 0.4000 (-4.08%)
Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 1.72% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AADI : 1.8400 (+1.10%)
TRVN : 0.4000 (-4.08%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.094 (+4.44%)
SILO : 1.9200 (-3.52%)
LLY : 807.43 (-0.13%)
ACOR : 0.6610 (-24.86%)
TRVN : 0.4000 (-4.08%)
IMRN : 2.25 (-2.71%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 1.9200 (-3.52%)
LLY : 807.43 (-0.13%)
ACOR : 0.6610 (-24.86%)
TRVN : 0.4000 (-4.08%)
IMRN : 2.25 (-2.71%)
Trevena (NASDAQ: TRVN) Partner Receives Approval for OLINVYK in China

Trevena, Inc. (NASDAQ: TRVN) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization of

TRVN : 0.4000 (-4.08%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

KNSA : 19.05 (-0.63%)
TRVN : 0.4000 (-4.08%)

Barchart Exclusives

Is Palo Alto Stock a Buy Right Now?
Cybersecurity stock Palo Alto got punished after lowering the upper rail of its billings guidance, but analysts say the sell-off was an overreaction. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar